Mavacamten
Brand names: Camzyos · Active ingredient: Mavacamten
In short: CAMZYOS is indicated for the treatment of adults and pediatric patients weighing 30 kg or more with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
What is Mavacamten used for?
CAMZYOS is indicated for the treatment of adults and pediatric patients weighing 30 kg or more with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
âš Boxed warning (FDA's strongest warning)
CAMZYOS reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction .
Echocardiogram assessments of LVEF are required prior to and during treatment with CAMZYOS. Initiation of CAMZYOS in patients with LVEF <55% is not recommended. Interrupt CAMZYOS if LVEF is <50% at any visit or if the patient experiences heart failure symptoms or worsening clinical status .
Concomitant use of CAMZYOS with certain cytochrome P450 inhibitors or discontinuation of certain cytochrome P450 inducers may increase the risk of heart failure due to systolic dysfunction; therefore, the use of CAMZYOS is contraindicated with the following :
•
Strong CYP2C19 inhibitors
•
Moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers
Because of the risk of heart failure due to systolic dysfunction, CAMZYOS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called CAMZYOS REMS PROGRAM .
Mavacamten dosage
Confirm absence of pregnancy and usage of effective contraception in females of reproductive potential .
Initiation or up-titration of CAMZYOS in patients with LVEF <55% is not recommended.
Initiation Dosage in Adult Patients
The recommended starting dose is 5 mg orally once daily without regard to food; allowable subsequent doses with titrations are 2.5 mg, 5 mg, 10 mg, or 15 mg orally once daily. The maximum recommended dose is 15 mg orally once daily.
Patients may develop heart failure while taking CAMZYOS. Regular LVEF and Valsalva left ventricular outflow tract (LVOT) gradient assessment is required for careful titration to achieve an appropriate target Valsalva LVOT gradient, while maintaining LVEF ≥50% and avoiding heart failure symptoms .
Daily dosing takes weeks to reach steady-state drug levels and therapeutic effects, and genetic variation in metabolism and drug interactions can cause large differences in exposure [see Boxed Warning, Contraindications (4), Warnings and Precautions (5.2), Drug Interactions (7.1) and Clinical Pharmacology (12.3)].
When initiating or titrating CAMZYOS, first consider LVEF then consider the Valsalva LVOT gradient and patient clinical status to guide appropriate CAMZYOS dosing. Assessment of post-exercise LVOT gradient may be considered in symptomatic patients with normal or near normal Valsalva gradients (approximately 30 mmHg) prior to initiating treatment with CAMZYOS. Follow the algorithms for Initiation (Figure 1) and Maintenance (Figure 3) for appropriate CAMZYOS dosing and monitoring schedules.
If LVEF <50% while taking CAMZYOS, interrupt treatment. Follow the algorithm for Interruption (Figure 4) for guidance on interrupting, restarting, or discontinuing CAMZYOS. If interrupted at 2.5 mg, either restart at 2.5 mg or discontinue permanently.
Figure 1: Initiation Phase for Adult Patients
Initiation Dosage in Pediatric Patients
The recommended starting dose is
•
5 mg orally once daily for pediatric patients weighing greater than or equal to 45 kg.
•
2.5 mg orally once daily for pediatric patients weighing 30 kg to less than 45 kg.
CAMZYOS was not studied in pediatric patients weighing less than 30 kg.
CAMZYOS is taken orally once daily without regard to food; allowable subsequent doses with titrations are 1 mg, 2.5 mg, 5 mg, 10 mg, or 15 mg. The maximum recommended dose is 15 mg orally once daily.
Follow the algorithms for Initiation (Figure 2) and Maintenance (Figure 3) for appropriate CAMZYOS dose adjustment and monitoring schedules in pediatric patients.
If LVEF <50% while taking CAMZYOS, interrupt treatment. Follow the algorithm for Interruption (Figure 4) for guidance on interrupting, restarting, or discontinuing CAMZYOS. …
How to take Mavacamten — instructions & advice from the label
Advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide).
Heart Failure
Inform patients that cardiac function monitoring must be performed using echocardiography to monitor for heart failure . Advise patients to report any signs or symptoms of heart failure immediately to their healthcare provider.
Drug Interactions
Advise patients to inform their healthcare providers of all concomitant products, including over-the-counter medications (such as omeprazole, esomeprazole, or cimetidine) and supplements, prior to and during CAMZYOS treatment.
CAMZYOS REMS Program
CAMZYOS is available only through a restricted program called the CAMZYOS REMS Program . Inform the patient of the following notable requirements:
•Patients must enroll in the program and comply with ongoing monitoring requirements .
CAMZYOS is only prescribed by certified healthcare providers and only dispensed from certified pharmacies participating in the program. Provide patients with the telephone number and website for information on how to obtain the product .
Embryo-Fetal Toxicity
Advise pregnant females and females of reproductive potential of the potential risk to a fetus. …
Warnings & precautions
Do not take this medicine if: CAMZYOS is contraindicated with concomitant use of:
•Strong CYP2C19 inhibitors
•Moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers
CAMZYOS reduces systolic contraction and can cause heart failure or significantly reduce ventricular function. Patients who experience a serious intercurrent illness (e.g., serious infection) or arrhythmia (e.g., atrial fibrillation or other uncontrolled tachyarrhythmia) are at greater risk of developing systolic dysfunction and heart failure .
Assess the patient’s clinical status and LVEF prior to and regularly during treatment and adjust the CAMZYOS dose accordingly . New or worsening arrhythmia, dyspnea, chest pain, fatigue, palpitations, leg edema, or elevations in N-terminal pro-B-type natriuretic peptide (NT-proBNP) may be signs and symptoms of heart failure and should also prompt an evaluation of cardiac function.
Asymptomatic LVEF reduction, intercurrent illnesses, and arrhythmias require additional dosing considerations .
Initiation of CAMZYOS in patients with LVEF <55% is not recommended. Avoid concomitant use of CAMZYOS in patients on disopyramide, ranolazine, verapamil with a beta blocker, or diltiazem with a beta blocker as these medications and combinations increase the risk of left ventricular systolic dysfunction and heart failure symptoms and clinical experience is limited .
CAMZYOS is primarily metabolized by CYP2C19 and CYP3A4 enzymes. Concomitant use of CAMZYOS and drugs that interact with these enzymes may lead to life-threatening drug interactions such as heart failure or loss of effectiveness .
Advise patients of the potential for drug interactions, including with over-the-counter medications (such as omeprazole, esomeprazole, or cimetidine). Advise patients to inform their healthcare provider of all concomitant products prior to and during CAMZYOS treatment . …
Mavacamten side effects
The following adverse reaction is discussed in other sections of the labeling:
•Heart failure
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of CAMZYOS was evaluated in EXPLORER-HCM, a phase 3, double-blind, randomized, placebo-controlled trial . Of the 251 adults with obstructive HCM, 123 patients were treated with CAMZYOS 2.5-15 mg daily and 128 were treated with placebo. CAMZYOS-treated patients had a median duration of exposure of 30 weeks (range: 2-40 weeks).
Syncope (0.8%) was the only adverse drug reaction leading to discontinuation in patients receiving CAMZYOS.
Adverse reactions occurring in >5% of patients and more commonly on CAMZYOS than on placebo were dizziness (27% vs. 18%) and syncope (6% vs. 2%).
The safety of CAMZYOS in patients was further evaluated in VALOR-HCM, a phase 3, double-blind, randomized, placebo-controlled trial . Of the 112 adults with symptomatic obstructive HCM, 56 patients were treated with CAMZYOS 2.5-15 mg daily and 55 were treated with placebo. CAMZYOS-treated patients had a median duration of exposure of 17 weeks (range: 3-19 weeks).
There were no new adverse reactions identified in VALOR-HCM. …
Drug interactions
Mavacamten is primarily metabolized by CYP2C19 and to a lesser extent by CYP3A4 and CYP2C9. Inducers and inhibitors of CYP2C19 and moderate to strong inhibitors or inducers of CYP3A4 may affect the exposures of mavacamten .
Table 1: Established and Potentially Significant Pharmacokinetic Drug Interactions with CAMZYOS
Impact of Other Drugs on CAMZYOS
Strong CYP2C19 Inhibitors
Clinical Impact | Concomitant use with a strong CYP2C19 inhibitor increases mavacamten exposure, which may increase the risk of heart failure due to systolic dysfunction .
Prevention or Management | Concomitant use with a strong CYP2C19 inhibitor is contraindicated.
Moderate to Strong CYP2C19 Inducers or Moderate to Strong CYP3A4 Inducers
Clinical Impact | Concomitant use with a moderate to strong CYP2C19 inducer or a moderate to strong CYP3A4 inducer decreases mavacamten exposure, which may reduce CAMZYOS’ efficacy . The risk of heart failure due to systolic dysfunction may increase with discontinuation of these inducers as the levels of induced enzyme normalizes .
Prevention or Management | Concomitant use of a moderate to strong CYP2C19 inducer or a moderate to strong CYP3A4 inducer is contraindicated. …
About this medicine
CAMZYOS capsules for oral use contain mavacamten, a cardiac myosin inhibitor.
The chemical name of mavacamten is 3-(1-methylethyl)-6-[[(1S)-1-phenylethyl]amino]-2,4(1H,3H)-pyrimidinedione. The molecular formula is C15H19N3O2, and the molecular weight is 273.33 g/mol.
The structural formula of mavacamten is:
Mavacamten is a white to off-white powder that is practically insoluble in water and aqueous buffers at pH 2-10, sparingly soluble in methanol and ethanol, and freely soluble in dimethyl sulfoxide and N-methyl-2-pyrrolidone.
CAMZYOS is supplied as immediate release Size 2 hard gelatin capsules, containing 1 mg, 2.5 mg, 5 mg, 10 mg, or 15 mg of mavacamten per capsule as active ingredient and the following inactive ingredients: croscarmellose sodium, hypromellose, magnesium stearate, mannitol, and silicon dioxide. The capsule shell contains black edible ink, ferric oxide red, ferric oxide yellow, ferrosoferric oxide, gelatin, and titanium dioxide.
How it works: Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 669c936b-3ee6-4e36-8a22-79dd11b1255b. Read the full official label on DailyMed.